Linifanib is a type I tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by linifanib (Hernandez-Davies et al, 2011; Nguyen et al, 2017).
Levis, M, Nguyen, B, Williams, AB, Small, D, Brown, P, Li, L, Young, DJ, Ma, H
Hernandez-Davies, JE, Sakamoto, KM, Heinrich, MC, Tan, X, Glaser, KB, Landaw, EM, Presnell, A, Zape, JP, Griffith, D
© 2023 Reactome